Gorilla Technology to Announce Full Year 2022 Results and Host Conference Call

LONDON, March 31, 2023 (GLOBE NEWSWIRE) — Gorilla Technology Group Inc. (“Gorilla”) (NASDAQ: GRRR), a global provider of AI-based edge video analytics, IoT technologies, and cybersecurity, announced today that the company’s full year 2022 financial results will be released after the U.S. financial markets close on Tuesday, April 4, 2023.

The Company will host a conference call on Wednesday, April 5, 2023 at 8:00 a.m. Eastern Time to discuss the Company’s financial results and financial guidance.

Participants can join by pre-registering for the conference call:

https://register.vevent.com/register/BId1e820d88a8c47e697a1491cc3d77ba2

Upon registering, you will be emailed a dial-in number and unique PIN.

About Gorilla Technology Group Inc.

Gorilla, headquartered in London U.K., is a global solution provider in security intelligence, network intelligence, business intelligence and IoT technology. Gorilla develops a wide range of solutions including Smart Cities, Smart Retail, Enterprise Security, and Smart Media. In addition, Gorilla provides a complete Security Convergence Platform to government institutions, telecom companies and private enterprises with network surveillance and cyber security.

Gorilla places an emphasis on offering leading technology, expert service, and precise delivery, and ensuring top-of-the-line, intelligent and strong edge AI solutions that enable clients to improve operational performance and efficiency. With continuous core technology development, Gorilla will deliver edge AI solutions to managed service providers, distributors, system integrators, and hardware manufacturers. For more information, please visit our website: Gorilla-Technology.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are based on estimates, assumptions, and expectations. Actual results and performance could differ materially and adversely from those expressed or implied in forward-looking statements. Gorilla does not undertake any obligation to update any forward-looking statements, except as required by law.

Contact:
Jeff Fox
The Blueshirt Group for Gorilla
+1 (415) 828-8298
jeff@blueshirtgroup.com

Gary Dvorchak, CFA
The Blueshirt Group Asia for Gorilla
+1 (323) 240-5796
gary@blueshirtgroup.com

GlobeNewswire Distribution ID 8799713

Telesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-up

New Releases Extend the BioXp® Select Product Line, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Synthetic Biology Workstation

SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced continued expansion of the BioXp® Select Kit product line, releasing two novel kits to enable DNA amplification and scale-up.

The BioXp® Select DNA Cloning and Amplification Kit and the BioXp® Select Plasmid Amplification Kit enable on-demand and automated synthesis and amplification of transfection-scale DNA beginning from the customers own DNA fragments or plasmid DNA, overnight and at the push of a button. This is expected to enable researchers to optimize their discovery workflows by reducing the time and steps for cloning and scale-up of DNA required for their testing and analysis.

“Common to many workflows is the need to scale DNA constructs to transfection-scale quantities. The BioXp® System enables one to automate cell-free DNA amplification and scale-up, reducing time and eliminating manual bacterial steps. We believe this can accelerate discovery, particularly in the areas of screening large number of lead candidates in antibody discovery, cellular immunotherapy, and protein engineering,” said Daniel Gibson, Ph.D., CTO and Co-founder of Telesis Bio.

“These releases represent our commitment to open our platform and provide scientists the flexibility to adapt the BioXp® System to their process and begin with their own materials. We believe that enabling scientists to begin the cloning, amplification, and mRNA synthesis process from their own linear DNA or plasmid DNA will empower them to advance their research and accelerate their discoveries. Throughout 2023, we plan to release additional BioXp® kits that enable cloning and DNA amplification, as well as to automate NGS Library Preparation and CRISPR gRNA synthesis,” said Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio.

For more information on BioXp® Select Amplification Kits or to place an order, please visit telesisbio.com/products/bioxp-kits/dna-amplification/

About Telesis Bio
Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® systems consolidate, automate, and optimize the entire synthesis, cloning and amplification workflow. As a result, they deliver virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com.

Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding Telesis Bio’s future financial performance as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 22, 2023. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.

Contact:
Jen Carroll
Vice President of Investor Relations
jen.carroll@telesisbio.com

GlobeNewswire Distribution ID 8799302

Marco Tognon wins the Superyacht Chef Competition at the Yacht Club de Monaco

MONACO, March 31, 2023 (GLOBE NEWSWIRE) — Marco Tognon won the Superyacht Chef Competition at the Yacht Club de Monaco. The event was held for the fourth year at the YCM in partnership with Bluewater and under the aegis of YCM’s La Belle Classe Academy training centre and the Monaco, Capital of Advanced Yachting approach. The culinary competition aimed to put the spotlight on gourmet cuisine at sea as being another facet of yachting professions. “It’s very important to us at the Yacht Club de Monaco to be a meeting platform for the industry and at the same time be able to combine the young generation with the owners. The network aspect is also very relevant in this kind of event,” said YCM secretary general, Bernard d’Alessandri. The award ceremony was held at the presence of the Prince Albert II of Monaco, president of the YCM.

Tognon, who is 29 years old and from Padua, has been cooking on yachts since 2017. He is currently the chef of Planet Nine, a 73-metre megayacht. He won the competition with a main course of lobster and a dessert of pineapple and mascarpone cream. “I am very happy to have joined this competition and I felt confident I could win. When I cook I am pragmatic and haven’t focused as much on what other people were doing as much as challenging myself,” he said.

The participants had to deal with a mystery basket and ‘last-minute’ ingredients chosen by the public. Chairing the 2023 edition was the two time three Michelin star chef Yannick Alléno, considered by many to be one of the world’s greatest chefs, with a strong focus on French cuisine and its heritage. He is also globally recognised for master-minding Modern Cuisine, a movement he initiated in 2013.  “You have to be very creative. When you are on board you have to cook breakfast, lunch, dinner and afternoon tea. It’s a huge work in a very small kitchen. I think it’s the most difficult position in the chef industry. In the competition we can see how they’re so creative. They don’t know the product and they only have 40 minutes to cook so they have to be very quick. We have to think about the waste. The food is so precious today so we have to think about it, of course,” added Alleno.

Among the professionals that came to judge the competition there were Chef Nicolas Petit (M/Y Latitude), winner in 2022, Chef Benoît Nicolas, ‘Meilleur Ouvrier de France’ 2015 in the gastronomic cuisine category, and Chef Cristina Bowerman, traditional Italian cuisine specialist influenced by her many experiences abroad. “I am glad to be here to be part of this jury. Many chef that I know have actually switched career from regular kitchens at the restaurant to board on yachts. You have to be very well organized and be very sensitive to every single ingredients in the kitchen. What I expected was not only a combination of flavors but also attention to sustainability. They’re sensitive to different way of cooking and saving plastic as well. I am certified plastic free and hope that everybody is gonna follow that trend and is going to be sensitive to this topic which is very important right now,” said Bowerman.

This year the nine superyacht chefs had to comply with anti-waste criteria requiring contestants to use every single ingredient in the mystery basket or receive a penalty, applied in accordance with an external scoring grid. British Chef Duncan Biggs who officiates on superyachts was in charge of this aspect of the competition.

For more information:
Press Office LaPresse ufficio.stampa@lapresse.it

A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/17db4d4e-7674-4b92-a94f-deba07446249

GlobeNewswire Distribution ID 8799550

Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates

SHANGHAI, China, March 31, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced financial results for the 2022 full year and provided corporate updates.

FINANCIAL HIGHLIGHTS

  • Total revenue was approximately RMB 1,453 million during 2022. Sales revenue from TUOYI® (toripalimab) alone was approximately RMB 736 million, representing an increase of approximately 79% compared to 2021. With the increase in commercialization capability, as well as the approval and launch of two more significant indications for TUOYI® in 2022, the company’s sales in the domestic market are gradually entering a positive cycle.
  • Total research and development (“R&D”) expenses were approximately RMB 2,384 million in 2022, representing an increase of approximately 15% compared to 2021. The increase in R&D expenses was mainly due to (i) the continuous increase in R&D investment and product pipeline enrichment; (ii) the acceleration in the progress of current clinical projects and development of reserved R&D projects; and (iii) the reservation of the R&D team.
  • Net cash from financing activities was approximately RMB 4,643 million in 2022, which was mainly attributable to the successful issuance of the company’s new A shares on the STAR Market of the Shanghai Stock Exchange on December 2nd, 2022. Net cash inflow from the issuance was RMB 3,748 million and new bank borrowings contributed a net cash inflow of RMB 840 million. These net cash inflows from financing activities fully covered the cash outflows from operating and investing activities, leading to the increase of RMB 2,492 million in bank balances and cash.
  • Loss attributable to the owners of the company was RMB 2,386 million in 2022, representing an increase of RMB 1,667 million compared to 2021. This increase was mainly due to out-licensing, which resulted in the decline of revenue.

BUSINESS HIGHLIGHTS

During 2022, we focused on addressing “unmet clinical needs” and have made original, innovative and breakthrough progress in the discovery, R&D, production and commercialization of innovative therapies and drugs. Our efforts have filled various gaps domestically and have positioned us as global leaders in some fields. The following are some of our greatest achievements and milestones in 2022:

  • Advancements in pipeline: The company’s innovative R&D field has expanded from monoclonal antibodies to the development of various drug modalities, including small molecules drugs, polypeptide drugs, antibody drug conjugates (ADCs), bi-specific or multi-specific antibodies and nucleic acid drugs, as well as the exploration of next-generation innovative therapies for cancer and autoimmune diseases. Product pipelines cover five major therapeutic areas, including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases and infectious diseases. In 2022, a total of four drugs (TUOYI®, JUNMAIKANG®, MINDEWEI (民得維®) and etesevimab) were commercialized in China or abroad, around 30 assets are undergoing clinical trials with ongericimab, bevacizumab and PARP inhibitor under Phase III clinical trials, and over 20 drug candidates are under pre-clinical drug development.
    • In February 2022, the dosing of the first patient was completed in the Phase III clinical trial of TUOYI® in combination with standard chemotherapy as the adjuvant treatment after radical resection of gastric or esophagogastric junction adenocarcinoma (JUPITER-15 study, NCT05180734).
    • In February 2022, the investigational new drug (“IND”) application for JS112 (Aurora A inhibitor) was approved by the National Medical Products Administration of China (the “NMPA”).
    • In March 2022, the marketing of JUNMAIKANG® (adalimumab) for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis was approved by the NMPA.
    • In March 2022, the results of three Phase I clinical studies examining MINDEWEI were published in Acta Pharmacologica Sinica, a renowned journal in the pharmaceutical industry. These results revealed that MINDEWEI exhibited satisfactory safety and tolerability in healthy subjects, had a rapid oral absorption rate, and could be administered orally under fasting or normal diet conditions.
    • In March 2022, the IND application for JS107 (recombinant humanized anti-Claudin18.2 monoclonal antibody-MMAE conjugate) was approved by the NMPA.
    • In March 2022, the IND application for JS001sc (a toripalimab subcutaneous injection formulation) was approved by the NMPA.
    • In April 2022, the IND application of TAB009/JS009 (recombinant humanized anti- CD112R monoclonal antibody injection) for the treatment of advanced solid tumors was approved by the United States Food and Drug Administration (the “FDA”).
    • In April 2022, the results from the pre-clinical in vivo efficacy study evaluating MINDEWEI as a potent inhibitor of respiratory syncytial virus were published online in Signal Transduction and Targeted Therapy (STTT, IF: 38.104), a journal under Nature.
    • In April 2022, TUOYI® was granted orphan-drug designation by the FDA for the treatment of small-cell lung cancer (“SCLC”), marking the fifth FDA orphan-drug designation obtained by TUOYI®.
    • In May 2022, the IND application for JS105, a PI3K-α inhibitor jointly developed by Risen (Suzhou) Biosciences Co., Ltd. (“Risen Biosciences”) and the company, was approved by the NMPA.
    • In May 2022, a Phase III registration clinical study (NCT05341609) comparing MINDEWEI to nirmatrelvir tablet/ritonavir tablets (namely PAXLOVID) for the early treatment of mild to moderate coronavirus disease 2019 (“COVID-19”) met its prespecified primary and secondary endpoints. The MINDEWEI group achieved a shorter median time to sustained clinical recovery and attained statistical superiority, providing compelling evidence for MINDEWEI’s ability to accelerate the remission of COVID-19 symptoms. The relevant research results were published online in a globally authoritative journal, The New England Journal of Medicine (NEJM, IF: 176.082).
    • In May 2022, the supplemental new drug application (“sNDA”) for TUOYI® in combination with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”) was approved by the NMPA.
    • In June 2022, the IND applications for JS116 (small molecule irreversible covalent inhibitor of KRASG12C) and JS113 (fourth-generation EGFR inhibitor) were approved by the NMPA.
    • In July 2022, the IND application for JS105 (PI3K-α inhibitor) was approved by the FDA.
    • In July 2022, the IND application for JS203 (recombinant humanized anti-CD20 and CD3 bispecific antibody) was approved by the NMPA.
    • In August 2022, the IND application for JS110 (XPO1 inhibitor) was approved by the FDA.
    • In August 2022, the IND application for TAB009/JS009 (recombinant humanized anti-CD112R monoclonal antibody injection) was approved by the NMPA.
    • In September 2022, the NMPA approved the sNDA for TUOYI® in combination with pemetrexed and platinum as the first-line treatment of unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”) that is negative for both epidermal growth factor receptor (“EGFR”) mutations and anaplastic lymphoma kinase (“ALK”) mutations. This marked the sixth indication for TUOYI® approved by the NMPA.
    • In October 2022, the IND application for JS015 (recombinant humanized anti-DKK1 monoclonal antibody injection) was approved by the NMPA.
    • In November 2022, the supplemental application for additional indications of JUNMAIKANG® (adalimumab) for the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis and pediatric Crohn’s disease was approved by the NMPA.
    • In December 2022, the marketing authorization applications (the “MAA”) for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC, as well as toripalimab in combination with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, were accepted by the European Medicines Agency (the “EMA”).
  • Update on external collaborations
    • In January 2022, under the exclusive license and commercialization agreement with Coherus BioSciences, Inc. (“Coherus”) in February 2021, Coherus initiated the procedure for exercising the option to obtain a license for the development of the recombinant humanized anti-TIGIT monoclonal antibody (TAB006/JS006) or any product containing TAB006/JS006 in the United States and Canada for the treatment or prevention of human diseases. Coherus made a one-time exercise payment of US$35 million to the company and will pay up to an aggregate of US$255 million upon reaching the corresponding milestones, plus 18% royalty on the annual net sales of any product that contains TAB006/JS006 in the collaboration territory.
    • In March 2022, the company entered into a licensing and cooperation agreement with Wigen Biomedicine Technology (Shanghai) Co., Ltd. (“Wigen Biomedicine”) where the company granted Wigen Biomedicine the licenses for four small molecule anti-tumor drugs, namely JS120 (second-generation irreversible IDH1 inhibitor), JS121 (SHP2 inhibitor), JS122 (second-generation irreversible FGFR2 selective inhibitor) and JS123 (ATR inhibitor), thus further expanding our pipeline layout in the field of cancer treatment.
    • In June 2022, the company established a cooperation with Sun Yat-sen University Cancer Center and obtained three patent applications, which included the “Application of a Bacterium in Preparation of a Synergist of an Immune Checkpoint Inhibitor” and their related technologies and rights by way of exclusive license.
    • In December 2022, the company entered into an exclusive license and commercialization agreement with Hikma MENA FZE (“Hikma”) and granted Hikma an exclusive license to develop and commercialize the toripalimab injection in all 20 Middle East and North Africa (“MENA”) markets, including Jordan, Kingdom of Saudi Arabia, United Arab Emirates, Qatar, Morocco and Egypt. The company may receive payments of up to an aggregate of US$12 million, along with high-teen tiered royalties of up to 20% of the net sales. In addition, the right of first negotiation was granted to Hikma for the future commercial rights of three drugs currently in the development phase in one or more countries within the collaboration territory.
  • Business operations
    • In May 2022, the NMPA approved the production base in Lingang, Shanghai to produce commercial batches of TUOYI® in parallel with the company’s Wujiang production base in Suzhou. The Shanghai Lingang Production Base was constructed in accordance with the CGMP standard, and its production capacity has now reached 42,000L following the addition of 12,000L of production capacity last year. By virtue of economies of scale, the addition of the Shanghai Lingang Production Base has expanded production capacity and given the company the potential advantage of competitive production costs.
    • In December 2022, the company completed the issuance of 70 million new A shares to 17 target subscribers at an issue price of RMB 53.95 per Share. The gross proceeds amounted to RMB 3,776.50 million, which will be allocated towards R&D projects for innovative drugs, Shanghai Junshi Biotech headquarters and R&D base project.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. As of December 3 2021, over 700,000 patients have been treated with bamlanivimab or bamlanivimab and etesevimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has about 3,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8799393

2023 Digital Therapeutics Alliance Inaugural Summit: DTx Industry Leaders Gather to Transform Global Healthcare

Held at the Washington D.C. Marriott at Metro Center June 7 – 9, 2023.The 3-day Summit programming will be facilitated by leaders from all facets of the DTx industry, including policymakers, manufacturers, payors, and other experts to guide innovation and equity in healthcare.

Arlington, VA, March 30, 2023 (GLOBE NEWSWIRE) — The Digital Therapeutics Alliance (DTA) is hosting its Inaugural Summit on June 7-9, 2023 at the Washington Marriott at Metro Center. Leaders from all facets of the digital therapeutics (DTx) ecosystem, including policymakers, clinicians, and payors, will join DTA members to discuss the challenges and opportunities of DTx integration into the healthcare system and identify optimized policy, reimbursement, and regulatory pathways to accelerate adoption.

The 3-day Summit programming will be facilitated by Andy Molnar, Chief Executive Officer of DTA, and feature keynote presentations, panel discussions, and interactive sessions that cover the advancement of DTx, the impact of healthcare policy, reimbursement and regulatory pathways, clinical evidence requirements, and patient access optimization.

DTA’s Chief Executive Officer, Andy Molnar states: “We are here to transform healthcare and deliver a new category of medicine to patients to improve their lives. The 2023 DTA Inaugural Summit brings together the leaders in healthcare innovation that are making these monumental changes. We are building viable frameworks with partners from Capitol Hill, the investment ecosystem, clinicians, health plans, patients, and caregivers.”

DTx products use evidence-based, clinically evaluated technologies to optimize clinical and health economic outcomes, deliver high quality therapies to underserved populations, and transform how patients understand, manage, and engage in their healthcare.

Leading into the Summit, US-focused DTA members and staff will convene in Washington D.C. to meet with congressional members and other influential parties to advocate for the Access to Prescription Digital Therapeutics Act (S. 723 and H.R. 1458).This bill seeks to create a new benefit category for digital therapeutics and ensure permanent coverage and reimbursement of DTx products by Medicare and Medicaid.

Everett Crosland, DTA board member and Chief Commercial Officer for Cognito Therapeutics, commented, “Given the rapidly evolving reimbursement environment, DTA’s 2023 Inaugural Summit offers the DTx industry an unprecedented opportunity to engage and advocate on the issues that matter most to our companies, patients, providers, and payor partners. I’m excited to speak about the emerging frameworks that are shaping our future.”

Event details and registration: 2023 DTA Inaugural Summit 

About DTA:

The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding, adoption, and integration of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org and follow us on LinkedIn.

Attachment

Autumn Brennan
Digital Therapeutics Alliance
608-304-8000
abrennan@dtxalliance.org

GlobeNewswire Distribution ID 8799236

ResMed Chief Administrative Officer and Global General Counsel to Retire

  • ResMed to conduct an internal search for a successor general counsel
  • Amy Wakeham appointed Chief Communications and Investor Relations Officer, will join ResMed’s executive leadership team

SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) — ResMed (NYSE: RMD, ASX: RMD) announced today that David Pendarvis, chief administrative officer, global general counsel, and secretary, plans to retire, effective June 30, 2023. He will remain in a consulting role with ResMed through December 31, 2023.

ResMed will conduct an internal search for the successor to Pendarvis’ legal roles and expects to name a new global general counsel and secretary well ahead of David’s retirement date to ensure a smooth and seamless transition. Amy Wakeham, ResMed’s current Vice President of Corporate Communications & Investor Relations, has been appointed Chief Communications and Investor Relations Officer to succeed Pendarvis in his role leading corporate public affairs; she will report to the Office of the CEO and will join ResMed’s executive leadership team, effective April 1, 2023.

“Dave has been an integral part of ResMed for over 20 years, helping guide the company into and through its transformation from the pioneer of sleep apnea treatment to a $30 billion-plus global leader in digital health and cloud-connected medical devices,” said CEO Mick Farrell. “On behalf of the entire management team and the board, I want to thank Dave for his two decades of dedicated service and exemplary leadership that has helped build the industry-leading company that ResMed is today. He’s been an important leader in an executive team that has positioned ResMed to improve the lives of many millions of people living with chronic respiratory diseases and countless more seeking to age healthily and outside the hospital. Personally, Dave has been a trusted advisor, partner, friend, and mentor to me through the years, I will miss his guidance, insights, and quick sense of humor.”

“My best wishes to Dave on a much-deserved retirement, and congratulations to Amy on her well-earned appointment,” Farrell said. “Through an internal search process, we will identify a well-qualified successor for the global general counsel role ahead of Dave’s retirement to ensure a smooth transition into these critical roles. This speaks to the overall depth of ResMed’s leadership bench strength and broad expertise across our global team of over 10,000 ResMedians as we continue to execute our strategy that will help 250 million people sleep, breathe, and live healthier lives in 2025.”

Pendarvis, age 64, retires after a nearly 40-year career in law and business. He joined ResMed in 2002, following private practice as a partner with the firms of Gibson Dunn and Gray Cary Ware & Freidenrich (now DLA Piper). He has had several roles at ResMed: global general counsel, secretary, senior vice president of organizational development, chief administrative officer, and interim president – Europe, Middle East, Africa, and Japan.

About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies” and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

For media For investors
news@resmed.com investorrelations@resmed.com
+1 858.836.6798 +1 858.836.5000

GlobeNewswire Distribution ID 8799090